Intrathecal baclofen. Experimental and pharmacokinetic studies;Baclofène intrathécal. Historique, preuves expérimentales, et données pharmacocinétiques

Neurochirurgie

Volumn 49, Issue 2-3 II, 2003, Pages 271-275

  Sallerin, B ^a   Lazorthes, Y ^a  

^a CHU RANGUEIL   (France)

Author keywords

Baclofen; Intrathecal injections; Pharmacokinetics

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; CENTRAL MUSCLE RELAXANT;

BLOOD BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; CONFERENCE PAPER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; SIDE EFFECT; SPASTICITY; SPINAL CORD; STOMACH; TREATMENT OUTCOME; ANIMAL; INTRASPINAL DRUG ADMINISTRATION; REVIEW;

ANIMALS; BACLOFEN; GABA AGONISTS; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY;

EID: 0038743139     PISSN: 00283770     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. AHUJA S. Baclofen. Analytical Profiles of Drug Substances 1985; 14: 527-548.
2. ALBRIGHT AL, BARRON WB, FASICK MP, POLINKO P, JANOSKY J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 24: 2475-2477.
3. ALBRIGHT AL, CERVI A, SINGLETARY J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991; 265: 1418-1422.
4. ALBRIGHT AL, SHULT Z. Plasma baclofen levels in childreen receiving continuous intrathecal baclofen infusion. J Child Neurol 1999; 14: 408-409.
5. ASHBY P, WHITE DG. Presynaptic inhibition in spasticity and the effect of β(4-chlorophenyl) GABA. J Neurol Sci 1973; 20: 329-338.
6. BARBER RP, VAUGHN JE, ROBERTS E. The cytoarchitecture of GABAergiques neurons in the rat spinal cord. Brain Res 1982; 238: 305-322.
7. BARKER JL, NICOLL RA. Gamma-aminobutyric acid: role in primary afferent dépolarisation. Science 1972; 176: 1043-1045.
8. BENECKE R, MEYER-LOHMANN J. Effects of an antispastic drug (β-(4-chlorophenyl)-γ-aminobutyric acid) on Renshaw cell activity. Neuropharmacology 1974; 13: 1067-1075.
9. BOWERY NG, HILL DR, HUDSON AL, DOBLE A, MIDDLEMISS DN, SHAW JS, TURNBULL M. (-) baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 1980; 283: 92-94.
10. BOWERY NG, DOBLE A, HILL DR, HUDSON AL, SHAW JS, TURNBULL MJ, WARRINGTON R. Bicuculline insensitive GABA receptors on peripheral automatic nerve terminals. Eur. J. Pharmacol 1981; 71: 53-70
11. BOWERY NG. Baclofen, 10 years on. Tips 1982; 400-403.
12. BOWERY N, HILL DR, HUDSON AL. Characteristics of GABA B receptor binding sites on rat whole brain synaptic membranes. Br J Pharmacol 1983; 78: 191-206.
13. BURKE D. A critical examination of the case for and against fusimotor involvement in disorders in muscle tone. In: DESMEDT JE, ed. Motor control mechanisms in health and disease. Vol 10. Progress in Clinical Neurophysiology. Basel: Karger, 1983: 133-150.
14. CURTIS DR, LODGE D, BORNSTEIN JC, PEET MJ. Selective effects of (-) baclofen on spinal synaptic transmission in the cat. Brain Res 1981; 42: 158-170.
15. CURTIS DR, HÖSLI L, JOHNSTON GAR. Pharmacological study of the depression of spinal neurons by glycine and related aminoacides. Expl Brain Res 1968; 6: 1-18.
16. DAVIDOFF RA, SEARS ES. The effects of Lioresal on synaptic activity in the isolated spinal cord. Neurology 1974; 24: 957-963.
17. DAVIDOFF RA. Antispasticity drugs: Mechanism of action. Ann Neurol 1985; 17: 107-116.
18. DAVIES J. Selective depression of synaptic excitation in cat spinal neurons by baclofen: an iontophoretic study. Br J Pharmacol 1981; 72: 373-384.
19. ECCLES JC, SCHMIDT R, WILLIS WD. Pharmacological studies on presynaptic inhibition. J Physiol 1963; 168: 500-530.
20. FAIGLE JW, KEBERLE H. The chemistry and kinetics of Lioresal. Postgrad Med 1972; 48 (suppl): 9-13.
21. FEHR H, BEINH. Sites of action of a new muscle relaxant (Baclofen, Lioresal®, CIBA 34 647-BA). J Intern Med Res 1973; 1,2: 36-47.
22. Fox S, KRNJEVC K, MORRIS ME, PUIL E, WERMAN R. Action of baclofen on mammalian synaptic transmission. Neuroscience 1978; 3: 495-515.
23. GEHLERT DR, YAMAMURA HI, WAMSLEY JK. Gammaaminobutyric B receptors in the rat brain: Quantitative autoradiographic localization using 3 (3H) (-) baclofen. Neurosc Lett 1985; 56: 183-188.
24. HUNT SP, KELLY JS, EMSON PC, KIMMEL JR, MILLER RJ, WU JY. An immunohistochemical study of neuronal populations containing neuropeptides or gamma-aminobutyrate within the superficial layers of the rat dorsal horn. Neuroscience 1981; 6: 1883-1898.
25. JOHNSTON GAR, HAILSTONE MH, FREEMAN CG. Baclofen: stereoselective inhibition of excitant amino-acid release. J Pharmacol 1980; 32: 230-231.
26. KNUTSSON E, LINDBLOM U, MARTENSSON A. Plasma and cerebro-spinal fluid levels of baclofen (Lioresal) at optimal therapeutic response in spastic paresis. J Neurol Sci 1974; 2: 473-484.
27. KROIN JS, PENN RD, BEISSENGER RL, ARZBACHER RC. Reduced spinal reflexes following intrathecal baclofen in the rabbit. Exp Brain Res 1984; 54: 191-194.
28. KROIN J, ALI A, YORK MT. the distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 1993; 33: 226-230.
29. MÜLLER H, ZIERSKI J, DRALLE D, KRAUB D, MUTSCHLER E. Pharmacokinetics of intrathecal baclofen, In: MÜLLER H, ZIERSKI J, PENN R, eds. Local spinal therapy of spasticity. Berlin, Heidelberg: Springer Verlag, 1988: 155-214.
30. PENN RD, KROIN JS. Intrathecal baclofen alleviates spinal cord spasticity (letter). Lancet 1984; 1: 1078.
31. PENN RD, KROIN JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985; 2: 125-127.
32. PENN RD, KROIN JS Long term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987; 66: 181-185.
33. PENN RD, COROS DM Management of spasticity by central nervous system infusion techniques. In: YOUMANS JR, ed. Neurological surgery, Vol 5. 4th ed. Philadelphia, PA: WB Saunders Company, 1996: 3687-3700.
34. PIERAU FK, ZIMMERMANN P. Action of a GABA-derivative on postsynaptic potentials and membrane properties of cat's spinal motoneurones. Brain Res 1973; 54: 376-380.
35. PRICE GW, WILKIN GP, TURNBULL MJ, BOWERY NG. Are baclofen sensitive GABA-B receptors present on primary afferent terminals of the spinal cord. Nature 1984; 307: 71-74.
36. SALLERIN-CAUTE B, LAZORTHES Y, MONSARRAT B, CROS J, BASTIDE R. C5F Baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol 1991; 40: 363-365.
37. WUIS EW, DIRKS RJM, VREE TB, VAN DER KLEYN E. High performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivatization with O-phtadialdéhyde. J Chrom 1985; 337: 341-350.
38. YOUNG RR, DELWAIDE PJ. Drug therapy: spasticity (part 1 and part 2). N Engl J Med 1981; 304: 28-33 et 96-99.
39. ZIEGLANGSBERGER W, HOWE JR, SUTOR B. The neuropharmacology of bacille. In: MÜLLER H, ZIERSKI J, PENN R, eds. Local spinal therapy of spasticity. Berlin, Heidelberg: Springer Verlag, 1988: 37-49.